BioSpace News Archive

Drug Development

Madrigal’s MGL-3196 Achieves Primary Endpoint in Patients With Biopsy-Proven Non-alcoholic Steatohepatitis (NASH) in Phase II Clinical Trial

In this trial, MGL-3196 demonstrated statistically significant results for the primary endpoint.

December 6, 2017
·
9 min read
Data MATRIX Starts Projects in USA And Europe

Data MATRIX team is about to start two new projects in the United States and Europe.

December 6, 2017
·
1 min read
Business

BioInvent and Transgene Collaborate on Next Generation Oncolytic Viruses Encoding an Anti-CTLA-4 Antibody to Treat Solid Tumors

Transgene entered a collaboration to co-develop next generation oncolytic virus (OV) candidates encoding an anti-CTLA-4 antibody sequence - potentially with additional transgenes - capable of treating multiple solid tumors.

December 6, 2017
·
7 min read
Biotech Bay

Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Portola granted to Mr. Lawrence an award in the form of 5,000 restricted stock units.

December 6, 2017
·
1 min read
Pharm Country

Children’s Hospital of Philadelphia Release: Brain Remaps Itself in Child With Double Hand Transplant

The first child to undergo a successful hand transplant also is the first child in whom scientists have detected massive changes in how sensations from the hands are represented in the brain.

December 6, 2017
·
6 min read
Business

CVD Completes Purchase of 180,000 Sq. Ft. Facility

This new facility will be the primary manufacturing center for the Company’s wholly owned subsidiary, CVD Materials Corporation.

December 6, 2017
·
3 min read
Pharm Country

The Leukemia Lymphoma Society Achieves New Milestones in Offensive Against Acute Myeloid Leukemia, Deadly Blood Cancer

More than 150 patients are now enrolled in this innovative trial which aims to find new treatments for a blood cancer that has not seen significant treatment improvements in almost 40 years.

December 6, 2017
·
6 min read
Business

Neumentum Raises $6 Million in Series A Funding to Develop Non-opioid Pain Products and Requests Type B Meeting with FDA

Neumentum announced that it has raised $6 million in a Series A funding round through the sale of Series A Convertible Preferred Stock. Brookline Capital Markets acted as the exclusive placement agent for the financing.

December 6, 2017
·
5 min read